EDP-305

EDP-305
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 1-(4-tert-Butylphenyl)sulfonyl-3-[(3R)-3-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl]urea;
PubChem CID	121428882;
Chemical and physical data
Formula	C36H58N2O5S
Molar mass	630.93 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCNC(=O)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C)C)C)O;
	InChI InChI=1S/C36H58N2O5S/c1-8-26-30-21-24(39)15-18-36(30,7)29-16-19-35(6)27(13-14-28(35)31(29)32(26)40)22(2)17-20-37-33(41)38-44(42,43)25-11-9-23(10-12-25)34(3,4)5/h9-12,22,24,26-32,39-40H,8,13-21H2,1-7H3,(H2,37,38,41)/t22-,24-,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1; Key:SJKLCUGQVVYDCX-HRNVLBFRSA-N;

EDP-305 is a non-bile acid farnesoid X receptor (FXR) agonist developed by Enanta Pharmaceuticals for non-alcoholic fatty liver disease.^[1]^[2] According to preclinical research CYP3A4 is the main enzyme used to metabolize the drug and there is a low potential for drug interactions.^[3]

References

^ Ratziu, Vlad; Rinella, Mary E.; Neuschwander-Tetri, Brent A.; Lawitz, Eric; Denham, Douglas; Kayali, Zeid; Sheikh, Aasim; Kowdley, Kris V.; Desta, Taddese; Elkhashab, Magdy; DeGrauw, Jeffery; Goodwin, Bryan; Ahmad, Alaa; Adda, Nathalie (March 2022). "EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study". Journal of Hepatology. 76 (3): 506–517. doi:10.1016/j.jhep.2021.10.018. PMID 34740705. S2CID 243483067.
^ An, Ping; Wei, Guangyan; Huang, Pinzhu; Li, Wenda; Qi, Xiaolong; Lin, Yi; Vaid, Kahini A.; Wang, Jun; Zhang, Shucha; Li, Yang; Or, Yat Sun; Jiang, Li-Juan; Popov, Yury V. (July 2020). "A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction". Liver International. 40 (7): 1655–1669. doi:10.1111/liv.14490. PMC 7384094. PMID 32329946.
^ Ahmad, Alaa; Adda, Nathalie (September 2022). "Assessment of drug–drug interaction potential with EDP -305, a farnesoid X receptor agonist, in healthy subjects". Clinical and Translational Science. 15 (9): 2146–2158. doi:10.1111/cts.13348. PMC 9468552. PMID 35675500.

Legal status

Legal status	Investigational
Identifiers
IUPAC name 1-(4-tert-Butylphenyl)sulfonyl-3-[(3R)-3-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl]urea
PubChem CID	121428882
Chemical and physical data
Formula	C₃₆H₅₈N₂O₅S
Molar mass	630.93 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCNC(=O)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C)C)C)O
InChI InChI=1S/C36H58N2O5S/c1-8-26-30-21-24(39)15-18-36(30,7)29-16-19-35(6)27(13-14-28(35)31(29)32(26)40)22(2)17-20-37-33(41)38-44(42,43)25-11-9-23(10-12-25)34(3,4)5/h9-12,22,24,26-32,39-40H,8,13-21H2,1-7H3,(H2,37,38,41)/t22-,24-,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1 Key:SJKLCUGQVVYDCX-HRNVLBFRSA-N